Loading…
← CockpitCompetitor Analysis › 300601.SZ Shenzhen Kangtai Biological Products Co. Ltd. Class AOpen in the cockpit ↗

Shenzhen Kangtai Biological Products Co. Ltd. Class A300601.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese vaccine maker producing hepatitis B, HPV (under GSK license) and other vaccines for the domestic market.

≈ A Chinese vaccine maker partnered with GSK for HPVMomentum strong 65
Mkt cap
$1.86B
US dollars, full cap
Free float
67%
of shares outstanding
$/day
$25.4M
20-day average traded
Fwd P/E
105.5×
forward earnings
ROIC−WACC
-6.3 pp
WACC 10.0%
Hurdle
+19 pp
Req g minus delivered
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥11.41
1D-0.2%
1W-9.2%
1M-7.8%
3M-10.7%
6M-19.9%
YTD-22.8%
1Y-33.3%
ATR %3.7%
52w lowhigh35.8% off high

What Shenzhen Kangtai Biological Products does

Chinese vaccine maker producing hepatitis B, HPV (under GSK license) and other vaccines for the domestic market.

Sells vaccines mainly to provincial disease-control centres, which distribute them to local clinics: government-program vaccines are bought at tendered prices, while optional ones are paid for by the person vaccinated. Exposure to optional vaccines such as HPV and pneumococcal shots depends on consumer willingness to pay.

In one line: A Chinese vaccine maker partnered with GSK for HPV.

Products and services

  • Hepatitis B vaccine
  • HPV vaccine (GSK-licensed Cervarix)
  • 13-valent pneumococcal vaccine

Customers

  • CDC/vaccination centers
  • Hospitals

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Vaccines

What could go right

  • HPV/pneumococcal vaccination growth

What could go wrong

  • Vaccine procurement price pressure
  • GSK licensing dependency

Moat: narrow (regulatory licence, distribution). Exclusive domestic distribution of GSK's Cervarix HPV vaccine plus its own vaccine manufacturing base.

Headquarters: Shenzhen, China · Employees: 1,957

Named competitors

Shenzhen Kangtai Biological Products at a glance

Size Shenzhen Kangtai Biological Products (300601.SZ) is a China Health Care company (Biotechnology) with a market value of $1.86B, the 1247th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.41 on 18 Nov 2026.

Performance Over six months the shares fell 19.9%, against -3.6% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 19 in its peer set.

Growth Revenue fell 9.1% over the last twelve months (peer median +18.8%); the operating margin is 5.8% (peer median -58.6%).

Valuation It trades at 105.5× forward earnings against a peer median of 18.1× (most expensive of 6).

Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 6.3 points below its cost of capital (10.0% WACC).

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 97300601.SZ 82
Six months, rebased to 100: Shenzhen Kangtai Biological Products against the median of its 20 peers (local-currency closes).

Shenzhen Kangtai Biological Products financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.45BCN¥2.66BCN¥2.64BCN¥3.46BCN¥3.15B
Revenue growth—+1%-24%+10%—
Gross profitCN¥1.91BCN¥1.74BCN¥1.97BCN¥2.84BCN¥2.56B
EBITDAn/aCN¥468MCN¥469MCN¥1.02BCN¥431M
Net incomeCN¥117MCN¥70.3MCN¥202MCN¥861M-CN¥133M
Free cash flowCN¥180MCN¥499MCN¥188MCN¥375M-CN¥720M
Capital expenditureCN¥441MCN¥332MCN¥472MCN¥718MCN¥1.31B
Total debtCN¥1.98BCN¥1.99BCN¥2.20BCN¥2.55BCN¥2.40B

Quarterly statements and history in the cockpit →

Shenzhen Kangtai Biological Products competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%VERATRAXSEPNREPLBCRXCOAG688520MRVITRVIZBIORXRXSTOKALMR300601.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Shenzhen Kangtai Biological Products is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%50×100×BCRX688046AUPH145020600226300601.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shenzhen Kangtai Biological Products is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%BCRX688046AUPH145020300601.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shenzhen Kangtai Biological Products is the large dot.

Shenzhen Kangtai Biological Products competitors and peer comparison

Head to head with its named competitors (300601.SZ vs 300122.SZ vs 603392.SS vs 300142.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shenzhen Kangtai Biological Products 300601.SZ$1.86B-20%-9%6%105.5×22.7%
Chongqing Zhifei Biological Products 300122.SZ$5.28B-1%-28%-210%n/a-6.5%
Beijing Wantai Biological Pharmacy Enterprise 603392.SS$4.20B-43%+8%-35%n/an/a
Walvax Biotechnology 300142.SZ$2.48B-26%-23%5%348.7×29.5%
GSK GSK.L$97.9B-3%+4%25%10.4×-0.1%

How Shenzhen Kangtai Biological Products compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shenzhen Kangtai Biological Products against its 20 peers (data as of 18 Nov 2026)
Measure300601.SZPeer medianRank in peer set
1-month return-7.8%-1.1%8th lowest of 20
6-month return-19.9%-3.6%6th lowest of 19
Distance from 52-week high-35.8%-33.4%8th lowest of 21
Revenue growth (TTM)-9.1%+18.8%6th lowest of 15
Operating margin5.8%-58.6%5th highest of 15
Forward P/E105.5×18.1×most expensive of 6
Growth the price implies (Req g, 7 yrs)22.7%-3.7%2nd most demanding of 5
Growth delivered (Del g)+3.4%+33.1%lowest of 5
Hurdle (Req g minus delivered)+19.3 pp-32.5 ppmost demanding of 5
ROIC minus cost of capital-6.3 pp-9.9 pp4th highest of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shenzhen Kangtai Biological Products 300601.SZChina$1.86B-20%-9%6%105.5×22.7%+3.4%
Vera Therapeutics VERAUnited States$1.85B-26%n/a-4,160%n/an/an/a
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%n/an/an/a
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%11.1×-11.0%+117.9%
Hemab Therapeutics COAGUnited States$1.83B+48%n/an/an/an/an/a
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%n/an/an/a
Lycia Therapeutics LYCAUnited States$1.81Bn/a-55%-593%n/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%n/an/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%n/an/an/a
GemPharmatech 688046.SSChina$1.78B+39%+25%22%51.9×33.0%+24.8%
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%n/an/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%n/an/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%18.1×3.5%+41.4%
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%18.1×-12.1%+15.0%
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/an/an/an/a
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%27.6×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%n/an/an/a

Questions

Who are Shenzhen Kangtai Biological Products's main competitors?
Named competitors: Chongqing Zhifei Biological Products (300122.SZ), Beijing Wantai Biological Pharmacy (603392.SS), Walvax Biotechnology (300142.SZ), GSK (GSK.L). The cockpit's measured peer set (industry) also includes Vera Therapeutics (VERA), First Tracks Biotherapeutics (TRAX), Septerna (SEPN), Replimune (REPL), BioCryst Pharmaceuticals (BCRX), Hemab Therapeutics (COAG).
Is Shenzhen Kangtai Biological Products expensive compared with its peers?
On forward p/e it trades at 105.5× against a peer median of 18.1×, most expensive of 6 in its peer set. For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Shenzhen Kangtai Biological Products stock performed?
Over six months to 18 Nov 2026 the shares returned -19.9% against -3.6% for the median peer; over one year -33.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.